Find Clinical Trials

Back My cancer has not gone away or has come back Cancer progressed on treatment

Answer each question to find trials that best match your clinical situation. You can leave questions blank if you do not know the answer.

This search will output a list of trials for which you may be eligible based on the criteria you enter.

I want to enter information about my cancer and treatments

I want to enter information about my genetic testing (e.g, BRCA) and/or tumor testing results

I want to filter the trials based on location, phase of development, or drug name, category or target

Return only trials with results

Include all Phase 1 trials (i.e., dose-finding as well as expansion)

Matching Trials

For more detailed information please click on the clinical trial number and you will be taken to the clinicaltrials.gov website.
For a key to the icons and text used in the Results column, please click here.
To learn more about our trial annotation process, results assignments, and the criteria used to highlight drugs with promising results, please click here.

III

Recurrent ovarian cancer

Avastin Plus Chemotherapy vs. Avastin Plus Chemotherapy Chosen by Cancer Stem Cell Chemosensitivity Testing in the Management of Patients With Recurrent Platinum-Resistant or -Sensitive Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

MS, WV

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Bevacizumab	immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin	VEGF antagonist	Approved in Ovarian Cancer
Carboplatin	Paraplatin, Novoplatinum	DNA damaging agent	Approved in Ovarian Cancer
Cisplatin	CACP, cis-DDP, cis-platinum, CDDP, Platinol, Abiplatin, Blastolem, Briplatin, Cisplatyl, Citoplatino, Citosin, Lederplatin, Metaplatin, Neoplatin, Placis, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platiran, Platistin, Platosin	DNA damaging agent	Approved in Ovarian Cancer
Docetaxel	Taxotere	Microtubule stabilizer/mitotic inhibitor	Approved in Other Cancers
Gemcitabine	Gemzar	Ribonucleotide reductase and DNA synthesis inhibitor	Approved in Ovarian Cancer
Liposomal doxorubicin	Pegylated Liposomal Doxorubicin Hydrochloride, liposomal doxorubicin, LipoDox, Evacet, Dox-SL, Doxil	Topoisomerase II inhibitor	Approved in Ovarian Cancer
Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Microtubule stabilizer/mitotic inhibitor	Approved in Ovarian Cancer
Topotecan	Hycamptamine, Hycamtin, TOPO	Topoisomerase I inhibitor	Approved in Ovarian Cancer

III

Recurrent ovarian cancer, excluding primary platinum refractory

ENGOT-ov50 / GOG-3029 / INNOVATE-3: Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 200kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer

AZ, CA, CO, FL, GA, IA, KY, MD, MA, MN, MO, NE, NV, NJ, NC, OH, OR, PA, RI, SD, TX, VA, WA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Microtubule stabilizer/mitotic inhibitor	Approved in Ovarian Cancer
TTfields	NovoTTF-100L(O)	Microtubule destabilizer/mitotic inhibitor	Clinical Trials

IIa

Recurrent ovarian cancer

A Phase 1/2a Evaluation of the Safety and Efficacy of Adding AL3818, a Dual Receptor Tyrosine Kinase Inhibitor, to Standard Platinum-Based Chemotherapy, in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002)

CA, FL, LA, TX

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Anlotinib	Catequentinib, AL3818	VEGFR2/3 kinase inhibitor	Clinical Trials
Carboplatin	Paraplatin, Novoplatinum	DNA damaging agent	Approved in Ovarian Cancer
Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Microtubule stabilizer/mitotic inhibitor	Approved in Ovarian Cancer

II

Partially platinum sensitive or resistant ovarian cancer (for combo w/ rucaparib patients have to be BRCA WT and have no prior PARP inhibitor)

A Phase II Study With a Safety lead-in of Nivolumab in Combination With Bevacizumab or in Combination With Bevacizumab and Rucaparib for the Treatment of Relapsed Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer

MA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Bevacizumab	immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin	VEGF antagonist	Approved in Ovarian Cancer
Nivolumab	BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers
Rucaparib	AG-014699, PF 01367338, CO-338, Rubraca	PARP inhibitor	Approved in Ovarian Cancer

II

Granulosa cell ovarian cancer

A Phase I/II Trial of TRC102 (Methoxyamine HCl) in Combination With Temozolomide in Patients With Relapsed Solid Tumors and Lymphomas

MD

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Methoxyamine	TRC102	Base excision repair inhibitor	Clinical Trials
Temozolomide	Temodal, Temodar, Methazolastone	DNA damaging agent	Approved in Other Cancers

II

Recurrent ovarian cancer with dMMR, high MSI or high TMB

An Exploratory Study of Nivolumab With or Without Ipilimumab According to the Percentage of Tumoral CD8 Cells in Participants With Advanced Metastatic Cancer

CA, MA, NY, TX

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Ipilimumab	Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy	Blocks CTLA-4 inhibition of T cells	Approved in Other Cancers
Nivolumab	BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers

II

Advanced solid tumors with ARID1A (except clear cell) or ATM alterations

Phase II Trial of AZD6738 Alone and in Combination With Olaparib in Patients With Selected Solid Tumor Malignancies

CA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Ceralasertib	AZD6738, ATR kinase inhibitor AZD6738	ATR kinase inhibitor	Clinical Trials
Olaparib	AZD2281, Lynparza	PARP inhibitor	Approved in Ovarian Cancer

II

Advanced solid tumors with dMMR, high TMB or high MSI with limited progression on checkpoint inhibitor treatment

A Phase II Trial of Hypofractionated Radiotherapy in Patients With Limited Progression on Immune Checkpoint Blockade

CT, NJ, NY, PA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Atezolizumab	Tecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446	Blocks PD-L1 inhibition of T cells	Approved in Other Cancers
Ipilimumab	Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy	Blocks CTLA-4 inhibition of T cells	Approved in Other Cancers
Nivolumab	BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers
Pembrolizumab	Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers
Radiation Therapy	Radiotherapy, Irradiation

II

Advanced solid tumors with POLE, POLD, or BRCA1/2 mutations

A Basket Trial of Pembrolizumab in Patients With Advanced Solid Tumors and Genomic Instability

NJ

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Pembrolizumab	Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers

II

Recurrent ovarian cancer (excluding primary platinum refractory)

Combination ATR and PARP Inhibitor (CAPRI) Trial With AZD 6738 and Olaparib in Recurrent Ovarian Cancer

MD, MA, PA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Ceralasertib	AZD6738, ATR kinase inhibitor AZD6738	ATR kinase inhibitor	Clinical Trials
Olaparib	AZD2281, Lynparza	PARP inhibitor	Approved in Ovarian Cancer

II

Advanced solid tumors with lesion treatable with radiation therapy

Randomized Phase II Study of Checkpoint Blockade Immunotherapy Combined With Stereotactic Body Radiation Therapy in Advanced Metastatic Disease

CA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Atezolizumab	Tecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446	Blocks PD-L1 inhibition of T cells	Approved in Other Cancers
Ipilimumab	Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy	Blocks CTLA-4 inhibition of T cells	Approved in Other Cancers
Nivolumab	BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers
Pembrolizumab	Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers
Radiation Therapy	Radiotherapy, Irradiation

II

Advanced solid tumors with CDK12 alterations

IMPACT: Immunotherapy in Patients With Metastatic Cancers and CDK12 Mutations

CA, FL, MD, MI, MO, NY

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Ipilimumab	Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy	Blocks CTLA-4 inhibition of T cells	Approved in Other Cancers
Nivolumab	BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers

II

Recurrent ovarian cancer with progression on or after prior PARP inhibitor

EFFORT: Efficacy of AZD1775 in Parp Resistance; A Randomized 2-Arm, Non-Comparative Phase 2 Study of AZD1775 Alone or AZD1775 and Olaparib in Women With Ovarian Cancer Who Have Progressed During PARP Inhibition

MA, TX

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Adavosertib	WEE1 inhibitor AZD1775, MK1775, AZD1775	WEE1 inhibitor	Clinical Trials
Olaparib	AZD2281, Lynparza	PARP inhibitor	Approved in Ovarian Cancer

II

Advanced solid tumors with FGFR mutations or gene fusions

A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations

AZ, CO, DE, FL, GA, ME, MA, MI, NJ, NY, NC, OH, PA, TN, TX, WA, WI

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Erdafitinib	pan-FGFR tyrosine kinase inhibitor JNJ-42756493	pan-FGFR kinase inhibitor	Approved in Other Cancers

II

Recurrent carcinosarcoma

A Phase II Single Arm Study of Cabozantinib Plus Nivolumab and Ipilimumab in Women With Recurrent Gynecologic Carcinosarcoma

AL

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Cabozantinib	BMS-907351, Cabometyx, XL184, Cometriq	Multi-targeted RTK inhibitor	Approved in Other Cancers
Ipilimumab	Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy	Blocks CTLA-4 inhibition of T cells	Approved in Other Cancers
Nivolumab	BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers

II

Advanced solid tumors with mutations in BARD1, BRIP1, FANCA, NBN, RAD51, RAD51B, RAD51C or RAD51D, no prior PARP inhibitor

A Phase 2 Multicenter, Open-label Study of Rucaparib as Treatment for Solid Tumors Associated With Deleterious Mutations in Homologous Recombination Repair Genes

CA, FL, IL, IA, MA, MN, NY, OH, OK, PA, TN, TX, WA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Rucaparib	AG-014699, PF 01367338, CO-338, Rubraca	PARP inhibitor	Approved in Ovarian Cancer

II

Advanced solid tumors (amenable to radiation therapy)

Phase II Trial of Salvage Radiation Therapy to Induce Systemic Disease Regression After Progression on Systemic Immunotherapy

TX

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Radiation Therapy	Radiotherapy, Irradiation

II

Recurrent high grade serous ovarian cancer or carcinosarcoma

Clinical Study to Assess Efficacy and Safety of LN-145/LN-145-S1 (Autologous Centrally Manufactured Tumor Infiltrating Lymphocytes) Across Multiple Tumor Types

TX

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Aldesleukin	Proleukin	IL-2 receptor agonist	Approved in Other Cancers
Cyclophosphamide	Sendoxan, Procytox, Ledoxina, Genoxal, Fosfaseron, Enduxan, Endoxana, Endoxan, Cytophosphan, Cyclostine, Cyclostin, CYCLO-cell, Cycloblastine, Cycloblastin, Cicloxal, Carloxan, Neosar, Cytoxan, Clafen, Zytoxan, Syklofosfamid, Mitoxan, Cytophosphane, Cyclophosphanum, Cyclophosphan, Cyclophosphamidum, Cyclophosphamid monohydrate, Cyclophospham, CPM, CP monohydrate, Claphene, Ciclofosfamide, Ciclofosfamida	DNA damaging agent	Approved in Ovarian Cancer
Fludarabine	Fludara Oral, 2-F-ara-AMP, Beneflur	DNA synthesis inhibitor	Approved in Other Cancers
LN-145-S1	Autologous Tumor Infiltrating Lymphocytes LN-145-S1, PD-1 selected TIL therapy	Immune response against tumor-associated antigens	Clinical Trials

II

Advanced solid tumors with brain metastases and NTRK, ROS1, CDK pathway or PI3K pathway alterations

Genomically-Guided Treatment Trial in Brain Metastases

AK, AZ, AR, CA, CO, CT, FL, GA, ID, IL, IA, KY, LA, MA, MI, MN, MS, MO, MT, NE, NH, NJ, NM, NY, NC, OH, OK, OR, PA, TX, UT, VT, VA, WA, WI, WY

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Abemaciclib	Bemaciclib, LY2853219, CDK4/6 Dual Inhibitor LY2835219, Verzenio	CDK4/6 inhibitor	Approved in Other Cancers
Entrectinib	RXDX-101, TrkA/B/C/ROS1/ALK tyrosine kinase inhibitor RXDX-101, Rozlytrek	ALK, TRK, ROS1 kinase inhibitor	Approved in Other Cancers
Paxalisib	RG7666, PI3K inhibitor GDC-0084, GDC-0084	PI3K/mTOR inhibitor

II

Advanced solid tumors with FGFR mutations or translocations

A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumors Harboring Activating FGFR Mutations or Translocations (FIGHT-208)

CA, FL, HI, IL, MD, NJ, OH, SD, TX, UT

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Pemigatinib	FGFR inhibitor INCB054828, INCB054828, Pemazyre	FGFR1-3 inhibitor	Approved in Other Cancers

II

Recurrent ovarian cancer

A Phase II Study of Pembrolizumab Monotherapy in Recurrent Ovarian Cancer of the Immunoreactive Subtype Determined by NanoString Gene Expression Profiling

CA, MN

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Pembrolizumab	Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers

II

Platinum sensitive ovarian cancer with first or second recurrence in peritoneal cavity

Systemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian Cancer

PA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Cisplatin	CACP, cis-DDP, cis-platinum, CDDP, Platinol, Abiplatin, Blastolem, Briplatin, Cisplatyl, Citoplatino, Citosin, Lederplatin, Metaplatin, Neoplatin, Placis, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platiran, Platistin, Platosin	DNA damaging agent	Approved in Ovarian Cancer
Pembrolizumab	Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers
Rintatolimod	Atvogen	TLR3 agonist and immune cell stimulator	Approved in Other Indications

II

Recurrent low grade serous ovarian cancer

A Phase II Trial of Ribociclib (LEE011) Plus Letrozole in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary, Fallopian Tube or Peritoneum

CA, FL, GA, IL, IN, MN, NH, NJ, NM, OH, OK, PA, RI, TX

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Letrozole	Femara	Aromatase inhibitor	NCCN Guidelines for Ovarian Cancer
Ribociclib	Kisqali, CDK4/6 Inhibitor LEE011, LEE011, Kisqali	CDK4/6 inhibitor	Approved in Other Cancers

II

Recurrent or refractory high grade serous ovarian cancer or carcinosarcoma

Clinical Study to Assess Efficacy and Safety of MDA-TIL (Autologous Expanded Tumor Infiltrating Lymphocytes) Across Multiple Tumor Types

TX

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
MDA-TIL	autologous tumor-infiltrating lymphocytes MDA-TIL	Anti-tumor immune response	Clinical Trials

II

Advanced solid tumors (in ovarian expansion)

A Multicenter, Open-label Phase 2 Study of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) in Previously Treated Subjects With Selected Solid Tumors (LEAP-005)

CA, FL, NJ, NY, TN, WI

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Lenvatinib	E7080, ER-203492-00, Lenvima, MK-7902	VEGFR1-3 kinase inhibitor	Approved in Other Cancers
Pembrolizumab	Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers

II

Advanced solid tumors with ALK or ROS1 activating genomic aberrations

Phase II Study of Brigatinib for Advanced Solid Cancers Harboring Genomic Alterations in ALK (Excluding Lung) and ROS1 Oncogenes

OH

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Brigatinib	AP26113, Alunbrig	ALK and EGFR kinase inhibitor	Approved in Other Cancers

II

Advanced solid tumors with prior anti-PD-1/PD-L1 Ab

An Open-label, Phase II, Platform Trial Evaluating Safety and Efficacy of Multiple BI 754091 Anti-PD-1 Based Combination Regimens in PD-(L)1 naïve and PD-(L)1 Pretreated Patient Populations With Advanced and/or Metastatic Solid Tumours Who Have Had at Least One Line of Systemic Therapy

CA, FL, IN, KY, OK, TN, WI

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
BI 754091	anti-PD-1 monoclonal antibody BI 754091	Blocks PD-L1/2 inhibition of T cells	Clinical Trials
BI 754111		Blocks LAG-3 inhibition of T cells	Clinical Trials

II

Recurrent ovarian cancer

Phase II, Prospective Open Label, Single Arm Study to Investigate Anti-tumor Effect and Tolerability of 2X-121 in Patients With Advanced Ovarian Cancer Selected by the 2X-121 DRP®

MA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Stenoparib	PARP/Tankyrase inhibitor 2X-121, E7449, 2X-121	PARP inhibitor	Clinical Trials

II

Advanced solid tumors - intratumoral injection

A Phase II Randomized Trial of Intralesional Talimogene Laherparepvec (TALIMOGENE LAHERPAREPVEC) With or Without Radiotherapy for Cutaneous Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors

NJ, NY

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Radiation Therapy	Radiotherapy, Irradiation
Talimogene Laherparepvec	GM-CSF-encoding oncolytic herpes simplex virus, T-VEC	Induces immune response and tumor cell lysis	Approved in Other Cancers

II

Recurrent PR+ low grade serous or granulosa cell ovarian cancer

Basket Study of the Oral Progesterone Antagonist Onapristone ER (Apristor) in Women With Progesterone Receptor Positive (PR+) Recurrent Granulosa Cell Tumor, Low Grade Serous Ovarian Cancer or Endometrioid Endometrial Cancer

NJ, NY

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Onapristone ER	extended-release onapristone	PR antagonist that blocks PR activation and the associated expression of PR-responsive genes

II

Advanced solid tumors with moderate/high TMB

Phase 2 Investigation of MEDI4736 (Durvalumab) and Tremelimumab Combination in Somatically Hypermutated Recurrent Solid Tumors

KY

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Durvalumab	Anti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, Imfinzi	Blocks PD-L1 inhibition of T cells	Approved in Other Cancers
Tremelimumab	anti-CTLA4 human monoclonal antibody CP-675,206, CP-675, CP-675,206, CP-675206, Ticilimumab	Blocks CTLA-4 inhibition of T cells	Clinical Trials

II

Advanced solid tumors (with tumor amenable to skin biopsy)

DURVA+ : Evaluation of the Safety and Pharmacodynamics of Anti-PD-L1 Antibody MEDI4736 (Durvalumab) in Combination With Chemotherapy in Patients With Advanced Solid Tumors

MD

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Capecitabine	Xeloda, CAPE	RNA processing and thymidylate synthase inhibitor	NCCN Guidelines for Ovarian Cancer
Carboplatin	Paraplatin, Novoplatinum	DNA damaging agent	Approved in Ovarian Cancer
Durvalumab	Anti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, Imfinzi	Blocks PD-L1 inhibition of T cells	Approved in Other Cancers
Gemcitabine	Gemzar	Ribonucleotide reductase and DNA synthesis inhibitor	Approved in Ovarian Cancer
Liposomal doxorubicin	Pegylated Liposomal Doxorubicin Hydrochloride, liposomal doxorubicin, LipoDox, Evacet, Dox-SL, Doxil	Topoisomerase II inhibitor	Approved in Ovarian Cancer
nab-Paclitaxel	Paclitaxel Albumin-Stabilized Nanoparticle Formula, Abraxane, ABI-007	Microtubule stabilizer/mitotic inhibitor	NCCN Guidelines for Ovarian Cancer
Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Microtubule stabilizer/mitotic inhibitor	Approved in Ovarian Cancer

II

Advanced solid tumors with a NRG1 gene fusion

CRESTONE: A Phase 2 Study of Seribantumab in Adult Patients With Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors

AZ, CA, CO, FL, IL, MA, MI, MO, NY, NC, TN, TX, VA, WA, WI

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Seribantumab	SAR256212, MM-121	ERBB3 antagonist	Clinical Trials

II

Advanced solid tumors with dMMR, after prior immunotherapy

Phase II Study to Evaluate the Efficacy and Safety of Sirolimus in Subjects With Metastatic, Mismatch Repair Deficient Solid Tumors After Immunotherapy

NY

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Sirolimus	Rapamycin, Rapamune	mTOR inhibitor	Approved in Other Indications

II

Recurrent ovarian cancer with CCND1-3 or CDK4/6 AMP or CDKN2A alterations

An Open Label Phase II Study of the Efficacy and Safety of Abemaciclib, a Cyclin Dependent Kinase (CDK4/6) Inhibitor in Selected Patients With Recurrent Ovarian or Endometrial Cancer

CA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Abemaciclib	Bemaciclib, LY2853219, CDK4/6 Dual Inhibitor LY2835219, Verzenio	CDK4/6 inhibitor	Approved in Other Cancers
Anastrozole	Arimidex	Aromatase inhibitor
Letrozole	Femara	Aromatase inhibitor	NCCN Guidelines for Ovarian Cancer

II

Advanced HER2+ solid tumors

A Phase 2, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd, DS-8201a) for the Treatment of Selected HER2 Expressing Tumors (DESTINY-PanTumor02)

CA, IL, IN, MA, MI, NY, NC, TX, VA, WA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Trastuzumab deruxtecan	T-Dxd, DS-8201, fam-trastuzumab deruxtecan-nxki, ADC DS-8201a, anti-HER2 antibody-drug conjugate DS-8201a, anti-HER2 ADC DS-8201a, DS-8201a	ADC: anti-HER2 + topoisomerase I inhibitor (Dxd)	Approved in Other Cancers

II

Advanced CCR5+ solid tumors - subcutaneous injection of leronlimab with standard-of-care chemotherapy

Basket Study of Leronlimab (PRO 140) in Patients With CCR5+ Locally Advanced or Metastatic Solid Tumors

CA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Leronlimab	anti-CCR5 monoclonal antibody PRO 140	Modulates the tumor microenvironment and blocks tumor angiogenesis	Clinical Trials

II

Advanced solid tumors with alterations in BRAF, RAF1, MEK1/2, ERK1/2 or NF1

A Phase 2 Basket Trial of an ERK1/2 Inhibitor (LY3214996) in Combination With Abemaciclib for Patients Whose Tumors Harbor Pathogenic Alterations in BRAF, RAF1, MEK1/2, ERK1/2, and NF1.

IN

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Abemaciclib	Bemaciclib, LY2853219, CDK4/6 Dual Inhibitor LY2835219, Verzenio	CDK4/6 inhibitor	Approved in Other Cancers
LY3214996		ERK inhibitor	Clinical Trials

II

Advanced solid tumors with ATM mutations

A Modular Phase 2a Multicentre Open-Label Study to Investigate DNA-damage Response Agents (or Combinations) in Patients With Advanced Cancer Whose Tumours Contain Molecular Alterations (PLANETTE)

CA, FL, IN, MD, MA, MI, NV, NY, PA, SC

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Ceralasertib	AZD6738, ATR kinase inhibitor AZD6738	ATR kinase inhibitor	Clinical Trials

II

Recurrent ovarian cancer

Clinical and Immunologic Activity of ALKS 4230 on Tumor Microenvironment in Solid Tumor Patients - ARTISTRY-3

TX

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Nemvaleukin Alfa	intermediate-affinity interleukin-2 receptor agonist ALKS 4230, Nemvaleukin, ALKS4230	IL-2R beta and gamma agonist	Clinical Trials
Pembrolizumab	Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers

II

Recurrent platinum sensitive ovarian cancer with PARP inhibitor maintenance therapy following last platinum-based therapy

A Phase 2 Randomized, Multi-Centre Study to Investigate the Efficacy and Tolerability of a Second Maintenance Treatment in Patients With Platinum Sensitive Relapsed Epithelial Ovarian Cancer, Who Have Previously Received PARP Inhibitor Maintenance Treatment

AK, CA, CT, FL, GA, KY, LA, MI, MN, NJ, NY, OH, OK, OR, PA, RI, SC, SD, TX, VA, WA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Ceralasertib	AZD6738, ATR kinase inhibitor AZD6738	ATR kinase inhibitor	Clinical Trials
Olaparib	AZD2281, Lynparza	PARP inhibitor	Approved in Ovarian Cancer

II

Advanced solid tumors with alterations in AKT1/2/3, ALK, ERBB2, MDM2, NTRK1/2/3, PIK3CA (multiple mutations), ROS1 or with high TMB

Tumor-Agnostic Precision Immunooncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial

AL, CA, CO, DE, FL, GA, IN, ME, MI, MN, MO, NV, NH, NJ, NM, NY, NC, OH, OR, PA, SC, TN, TX, WA, WI

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Alectinib	AF802, anaplastic lymphoma kinase inhibitor CH5424802, Alecensa, ALK inhibitor CH5424802	ALK kinase inhibitor	Approved in Other Cancers
Atezolizumab	Tecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446	Blocks PD-L1 inhibition of T cells	Approved in Other Cancers
Entrectinib	RXDX-101, TrkA/B/C/ROS1/ALK tyrosine kinase inhibitor RXDX-101, Rozlytrek	ALK, TRK, ROS1 kinase inhibitor	Approved in Other Cancers
GDC-0077	RG6114	PI3K alpha inhibitor	Clinical Trials
Idasanutlin	MDM2 antagonist RO5503781, RG7388, RO5503781	MDM2 antagonist
Ipatasertib	GDC-0068, Akt Inhibitor GDC-0068, RG7440	pan-AKT inhibitor	Clinical Trials
Trastuzumab emtansine	trastuzumab-MCC-DM1 immunoconjugate, trastuzumab-MCC-DM1 antibody-drug conjugate, trastuzumab-MCC-DM1, trastuzumab-DM1, T-DM1, Kadcyla, ado trastuzumab emtansine	ADC: anti-HER2 + microtubule destabilizer (DM1)	Approved in Other Cancers

II

Recurrent low grade serous ovarian cancer with a KRAS mutation

A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Alone and In Combination With Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)

AZ, MN, OR, TX

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Defactinib	VS-6063, PF-04554878, PF-04554878	FAK inhibitor	Clinical Trials
VS-6766	CKI27, RO5126766, Raf/MEK dual kinase inhibitor RO5126766, CH5126766	RAF and MEK inhibitor	Clinical Trials

II

Advanced solid tumors with alterations in ATM, BACH1 (BRIP1), BARD1, BRCA 1/2, CDK12, CHK1/2, FANCA/B/C/D2/E/F/G/I/J/L/M/N, IDH1/2, MRE11A, NBN, PALB2, RAD50/51/51B/51C/51D or RAD54L (only 1 prior Pt-regimen; gBRCA MUT patients must have progressed on prior PARP inhibitor)

A Pharmacodynamics-Driven Trial of Talazoparib, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Aberrations in Genes Involved in DNA Damage Response

MD

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Talazoparib	MDV3800, BMN-673, Talazoparib Tosylate, Talzenna	PARP inhibitor	Approved in Other Cancers

II

Advanced solid tumors with alterations in AKT1/2/3, ALK, ERBB2, PIK3CA, PTEN, ROS1 or with high TMB or high MSI

MyTACTIC: An Open-Label Phase II Study Evaluating Targeted Therapies in Patients Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response

AZ, CA, CT, MI, MT, NE, NJ, NY, OH, OR, TN, WA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Alectinib	AF802, anaplastic lymphoma kinase inhibitor CH5424802, Alecensa, ALK inhibitor CH5424802	ALK kinase inhibitor	Approved in Other Cancers
Atezolizumab	Tecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446	Blocks PD-L1 inhibition of T cells	Approved in Other Cancers
Entrectinib	RXDX-101, TrkA/B/C/ROS1/ALK tyrosine kinase inhibitor RXDX-101, Rozlytrek	ALK, TRK, ROS1 kinase inhibitor	Approved in Other Cancers
GDC-0077	RG6114	PI3K alpha inhibitor	Clinical Trials
Ipatasertib	GDC-0068, Akt Inhibitor GDC-0068, RG7440	pan-AKT inhibitor	Clinical Trials
Pertuzumab	Perjeta, monoclonal antibody 2C4, rhuMAb2C4	HER2 dimerization inhibitor	Approved in Other Cancers
Trastuzumab	Herceptin, Anti-erbB2 Monoclonal Antibody, HER2 Monoclonal Antibody	HER2 antagonist	Approved in Other Cancers
Trastuzumab emtansine	trastuzumab-MCC-DM1 immunoconjugate, trastuzumab-MCC-DM1 antibody-drug conjugate, trastuzumab-MCC-DM1, trastuzumab-DM1, T-DM1, Kadcyla, ado trastuzumab emtansine	ADC: anti-HER2 + microtubule destabilizer (DM1)	Approved in Other Cancers
Tucatinib	Irbinitinib, ONT-380	HER2 kinase inhibitor	Approved in Other Cancers

II

Primary platinum resistant high grade ovarian cancer with no prior PARP inhibitor or recurrent high grade ovarian cancer with at least 2 prior therapies and with prior PARP inhibitor maintenance; no prior bevacizumab

Phase 2 Study to Evaluate the Safety & Efficacy of EP0057 in Combination With Olaparib in Advanced Ovarian Cancer Patients Who Have: Cohort 1 - Platinum Resistant Disease & Are PARP Inhibitor naïve; Cohort 2 - Had at Least 2 Prior Lines of Therapy Which Must Include at Least 1 Line of Platinum-based Chemotherapy Followed by PARP Inhibitor Maintenance

NY, TN, VA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
EP0057	IT-101, cyclodextrin-based polymer-camptothecin CRLX101, camptothecin-polymer conjugate IT-101, CRLX101, NLG207	Topoisomerase I inhibitor	Clinical Trials
Olaparib	AZD2281, Lynparza	PARP inhibitor	Approved in Ovarian Cancer

Ib/II

Primary platinum resistant ovarian cancer (at least 2 prior therapies) or recurrent clear cell ovarian cancer (at least 1 prior therapy), no prior VEGFR tyrosine kinase inhibitor

LIO-1: A Phase 1b/2, Open-Label Study to Evaluate the Safety and Efficacy of Lucitanib in Combination With Nivolumab in Patients With An Advanced, Metastatic Solid Tumor

CA, CO, FL, MA, NY, NC, OH, OK, PA, TN, WA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Lucitanib	VEGFR/FGFR dual kinase inhibitor E-3810	VEGFR and FGFR kinase inhibitor	Clinical Trials
Nivolumab	BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers

Ib/II

Platinum sensitive ovarian cancer

An Open Label, Multicenter, Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Carboplatin to Assess Safety, Tolerability, and Pharmacokinetics in Patients With Advanced or Metastatic Solid Tumors

CA, IL, IN, KS, NC, OH, TN, TX

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Carboplatin	Paraplatin, Novoplatinum	DNA damaging agent	Approved in Ovarian Cancer
Rebastinib	multitargeted tyrosine kinase inhibitor DCC-2036	Multi-targeted RTK inhibitor	Clinical Trials

Ib

Platinum sensitive or partially sensitive ovarian cancer with no prior gemcitabine

A Phase 1b, Multicenter Study to Determine the Dose, Safety, Efficacy and Pharmacokinetics of TRK-950 When Used in Combinations With Selected Anti-Cancer Treatment Regimens in Patients With Selected Advanced Solid Tumors

AZ, CA, LA, NJ, WI

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Carboplatin	Paraplatin, Novoplatinum	DNA damaging agent	Approved in Ovarian Cancer
Gemcitabine	Gemzar	Ribonucleotide reductase and DNA synthesis inhibitor	Approved in Ovarian Cancer
Nivolumab	BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers
Pembrolizumab	Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers
TRK-950	monoclonal antibody TRK-950	Undisclosed mechanism	Clinical Trials

Ib

Platinum sensitive BRCA WT ovarian cancer with ≤ 2 prior platinum therapies (in expansion)

A Phase Ib Study of Cobimetinib Administered in Combination With Niraparib, With or Without Atezolizumab, To Patients With Advanced Platinum-sensitive Ovarian Cancer

AZ, CA, FL, GA, MD, MO, NY, OK, TN, WI

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Atezolizumab	Tecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446	Blocks PD-L1 inhibition of T cells	Approved in Other Cancers
Cobimetinib	XL518, GDC-0973, Cotellic	MEK1 inhibitor	Approved in Other Cancers
Niraparib	MK4827, Zejula	PARP inhibitor	Approved in Ovarian Cancer

Ib

Newly diagnosed, persistent, or recurrent ovarian carcinosarcoma

Feasibility IB Trial of Paclitaxel/Carboplatin + Galunisertib (a Small Molecule Inhibitor of the Kinase Domain of Type 1 TGF-B Receptor) in Patients With Newly Diagnosed, Persistent or Recurrent Carcinosarcoma of the Uterus or Ovary

OK

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Carboplatin	Paraplatin, Novoplatinum	DNA damaging agent	Approved in Ovarian Cancer
Galunisertib	LY2157299	TGFBR1 antagonist	Clinical Trials
Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Microtubule stabilizer/mitotic inhibitor	Approved in Ovarian Cancer

Ib

Advanced solid tumors with BRCA1/2, ATM, BARD1, BRIP1, CDK12, CHEK2, FANCA, NBN, PALB2, RAD51B/C/D/L mutations (in expansion)

Combination Therapy of Rucaparib and Irinotecan in Cancers With Mutations in DNA Repair

CA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Irinotecan	Campothecin-11, Campto, Camptosar	Topoisomerase I inhibitor	NCCN Guidelines for Ovarian Cancer
Rucaparib	AG-014699, PF 01367338, CO-338, Rubraca	PARP inhibitor	Approved in Ovarian Cancer

I/IIa

Advanced NY-ESO-1+ solid tumors

A Phase I/IIa Study of TGFß Blockade in TCR-Engineered T-Cell Cancer Immunotherapy in Patients With Advanced Malignancies

NY

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Cyclophosphamide	Sendoxan, Procytox, Ledoxina, Genoxal, Fosfaseron, Enduxan, Endoxana, Endoxan, Cytophosphan, Cyclostine, Cyclostin, CYCLO-cell, Cycloblastine, Cycloblastin, Cicloxal, Carloxan, Neosar, Cytoxan, Clafen, Zytoxan, Syklofosfamid, Mitoxan, Cytophosphane, Cyclophosphanum, Cyclophosphan, Cyclophosphamidum, Cyclophosphamid monohydrate, Cyclophospham, CPM, CP monohydrate, Claphene, Ciclofosfamide, Ciclofosfamida	DNA damaging agent	Approved in Ovarian Cancer
Decitabine	dezocitidine, deoxyazacytidine, 5-aza-dCyd, Dacogen	DNA methylation inhibitor	Approved in Other Cancers
NY-ESO-1 reactive TCR retroviral vector transduced autologous PBL	anti-NY-ESO-1 TCR gene-engineered lymphocytes	Immune response against cancer expressing NY-ESO-1	Clinical Trials
TGFbeta DNRII-transduced Autologous Tumor Infiltrating Lymphocytes	TGFbeta Dominant Negative Receptor II transduced TILS	TGFbeta ligand trap, Anti-tumor immune response enhanced by TGFbeta inhibition	Clinical Trials

I/IIa

Advanced solid tumors

Phase 1/2a First-In-Human Study of BMS-986218 Monoclonal Antibody Alone and in Combination With Nivolumab in Advanced Solid Tumors

GA, MA, NJ, NY, PA, SD

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
BMS-986218		Blocks CTLA-4 inhibition of T cells	Clinical Trials
Ipilimumab	Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy	Blocks CTLA-4 inhibition of T cells	Approved in Other Cancers
Nivolumab	BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers

I/IIa

Advanced solid tumors (in expansion) - intratumoral injection

A Phase I/IIA, Multicentre, Two Parts, Open-Label Study Designed to Evaluate the Safety and Tolerability of Escalating Doses of AGI-134 in Unresectable/Metastatic Solid Tumours

CA, NJ, OR

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
AGI-134	αGal immunotherapy	Anti-tumor immune response

I/II

Advanced solid tumors

Phase I/II Trial of Ipilimumab or Nivolumab With BMS-986156 and Hypofractionated Stereotactic Radiation Therapy in Patients With Advanced Solid Malignancies

TX

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
BMS-986156		GITR (glucocorticoid-induced TNFR) agonist	Clinical Trials
Ipilimumab	Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy	Blocks CTLA-4 inhibition of T cells	Approved in Other Cancers
Nivolumab	BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers
Radiation Therapy	Radiotherapy, Irradiation

I/II

Platinum resistant or refractory ovarian cancer with dMMR, high MSI, BRCA MUT or other DDR alterations, or HRD+, with progressive disease during or after prior anti-PD-1/PD-L1 checkpoint inhibitor

A Dose-optimization, Exploratory Phase Ib/II Study to Assess Safety and Efficacy of the Second Mitochondrial-derived Activator of Caspases (SMAC) Mimetic Debio 1143, When Given in Combination With the Anti-PD-1 Antibody Nivolumab in Patients With Specific Solid Tumors Who Have Progressed During or Immediately After Anti-PD-1/PD-L1 Treatment

FL, IL, MA, MI, MO, NY, OH, PA, TX, WA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Debio 1143	IAP inhibitor AT-406, AT-406	SMAC mimetic and IAP antagonist	Clinical Trials
Nivolumab	BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers

I/II

Advanced solid tumors (in ovarian expansion) - subcutaneous injection

A Phase 1/2 Study of ALKS 4230 Administered Subcutaneously as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors - ARTISTRY-2 (001)

CA, DC, GA, MI, NY, NC, OH, PA, SC, TX

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Nemvaleukin Alfa	intermediate-affinity interleukin-2 receptor agonist ALKS 4230, Nemvaleukin, ALKS4230	IL-2R beta and gamma agonist	Clinical Trials
Pembrolizumab	Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers

I/II

Recurrent or persistent WT1+ ovarian cancer

A Phase 1/2 Study of Galinpepimut-S in Combination With Pembrolizumab (MK 3475) in Patients With Selected Advanced Cancers

CA, CO, FL, NJ, NY, OH, TX, VA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Galinpepimut-S	SLS 001, WT-1 analog peptide vaccine SLS-001	Immune response against cancer expressing WT1	Clinical Trials
Pembrolizumab	Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers

I/II

Advanced solid tumor with high MSI or dMMR - intratumoral injection

An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination With PD1 Blockade in Patients With Solid Tumors

AL, AZ, CA, FL, IA, KY, NY, OR, TN, UT, WA, WI

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Nivolumab	BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers
RP1	oncolytic virus RP1, A genetically modified oncolytic viral strain of the herpes simplex type 1 (HSV-1) virus	Induces immune response and tumor cell lysis	Clinical Trials

I/II

Advanced solid tumors with RET alterations

A Phase 1/2 Study of Oral LOXO-292 in Patients With Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With RET Activation (LIBRETTO-001)

AZ, CA, CO, CT, FL, GA, IL, LA, MD, MA, MI, MN, MO, NV, NY, NC, OH, OR, PA, TN, TX, UT, VA, WI

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Selpercatinib	LOXO-292, RET kinase inhibitor LOXO-292, Retevmo	RET-kinase inhibitor	Approved in Other Cancers

I/II

Recurrent, persistent or refractory high grade serous ovarian cancer with BRCA1/2 or dMMR, HRR gene alterations or LOH high score

A Phase I/II Evaluation of Olaparib in Combination With Durvalumab (Medi4736) and Tremelimumab in the Treatment of Recurrent Platinum Sensitive or Resistant or Refractory Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Patients Who Carry a BRCA1 or BRCA2 Mutation

NY

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Durvalumab	Anti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, Imfinzi	Blocks PD-L1 inhibition of T cells	Approved in Other Cancers
Olaparib	AZD2281, Lynparza	PARP inhibitor	Approved in Ovarian Cancer
Tremelimumab	anti-CTLA4 human monoclonal antibody CP-675,206, CP-675, CP-675,206, CP-675206, Ticilimumab	Blocks CTLA-4 inhibition of T cells	Clinical Trials

I/II

Recurrent ovarian cancer

Phase I/II Study of the Anti-Programmed Death Ligand-1 Antibody MEDI4736 in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Cancers

MD

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Cediranib	AZD2171, Cediranib maleate, Recentin	VEGFR1-3 kinase inhibitor	Clinical Trials
Durvalumab	Anti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, Imfinzi	Blocks PD-L1 inhibition of T cells	Approved in Other Cancers
Olaparib	AZD2281, Lynparza	PARP inhibitor	Approved in Ovarian Cancer

I/II

Extrapulmonary small cell ovarian cancer

A Phase I/II Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor in Small Cell Cancers

MD

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Berzosertib	ATR kinase inhibitor VX-970, VE-822, M6620, VX-970	ATR kinase inhibitor	Clinical Trials
Topotecan	Hycamptamine, Hycamtin, TOPO	Topoisomerase I inhibitor	Approved in Ovarian Cancer

I/II

Advanced solid tumors with a RET alteration

A Phase 1/2 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors

AZ, CA, CO, DC, FL, MD, MA, MI, MN, MO, NY, OR, PA, TX, WA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Pralsetinib	BLU-667	RET-kinase inhibitor	Approved in Other Cancers

I/II

Advanced solid tumors with ALK, ROS1 or NTRK1-3 alterations

A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)

CA, CO, DC, FL, GA, IL, MD, MA, MI, MN, MO, NJ, NY, OH, PA, TX, VA, WA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Repotrectinib	ALK/ROS1/NTRK/SRC multi-kinase inhibitor TPX-0005, TPX-0005	ALK, ROS1, NTRK1-3, SRC and FAK kinase inhibitor	Clinical Trials

I/II

Advanced solid tumors with oncogenic activation of the NF-κB pathway or amplification of c-IAP1 or c-IAP2

Phase 1-2 Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas

AL, CA, CT, GA, IL, MD, MA, NH, NY, NC, OH, OK, OR, PA, TN, TX, WA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Tolinapant	XIAP/cIAP1 antagonist ASTX660, ASTX660	IAP antagonist	Clinical Trials

I/II

Advanced solid tumors with MET AMP or MET gene fusions

Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects With Non-Small Cell Lung Cancer With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

AZ, CA, DE, FL, LA, MD, MA, MN, MO, NC, OH, PA, SC, TN, UT, WA, WV, WI

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Bozitinib	CBT-101, APL-101	c-Met kinase inhibitor	Clinical Trials

I/II

Recurrent ovarian cancer

Phase 1/2 Study of REGN5668 (MUC16xCD28, a Costimulatory Bispecific) Administered in Combination With Cemiplimab or REGN4018 (MUC16xCD3)

Contact research study staff

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Cemiplimab	anti-PD-1 monoclonal antibody REGN2810, REGN2810, Libtayo	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers
REGN4018	anti-MUC16/CD3 bispecific antibody REGN4018	Re-directs T cells to attack MUC16 (CA125)+ tumor cells	Clinical Trials
REGN5668		Stimulates CD28 to increase T cell activation and immune response against MUC16 (CA125) expressing tumor cells	Clinical Trials

I

Recurrent serous ovarian cancer

A Phase I/Ib Trial of the CDK4/6 Antagonist Ribociclib And The HDAC Inhibitor Belinostat In Patients With Metastatic Triple Negative Breast Cancer And Recurrent Ovarian Cancer With Response Prediction By Genomics (CHARGE)

UT

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Belinostat	PXD101	HDAC inhibitor	Approved in Other Cancers
Ribociclib	Kisqali, CDK4/6 Inhibitor LEE011, LEE011, Kisqali	CDK4/6 inhibitor	Approved in Other Cancers

I

Recurrent ovarian cancer (with peritoneal disease)

Safety and Efficacy of Pressurized Intraperitoneal Aerosolized Chemotherapy (PIPAC) in Ovarian, Uterine, Appendiceal, Colorectal, and Gastric Cancer Patients With Peritoneal Carcinomatosis (PC)

CA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Cisplatin	CACP, cis-DDP, cis-platinum, CDDP, Platinol, Abiplatin, Blastolem, Briplatin, Cisplatyl, Citoplatino, Citosin, Lederplatin, Metaplatin, Neoplatin, Placis, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platiran, Platistin, Platosin	DNA damaging agent	Approved in Ovarian Cancer
Doxorubicin	14-Hydroxydaunomycin, Hydroxyl-Daunorubicin	Topoisomerase II inhibitor	Approved in Other Cancers

I

Recurrent ovarian cancer, excluding primary platinum refractory

Intraperitoneal FATE FT516 and Interleukin-2 (IL-2) With Intravenous Enoblituzumab in Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

Contact research study staff

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Aldesleukin	Proleukin	IL-2 receptor agonist	Approved in Other Cancers
Enoblituzumab	mab MGA271, MGA271	Immune response against cancer expressing B7H3	Clinical Trials
FT516	iPSC-derived non-cleavable CD16 (hnCD16) Fc receptor expressing NK cells FT516	Anti-tumor immune response	Clinical Trials

I

Partially platinum sensitive, platinum resistant or refractory ovarian cancer

A Phase I Dose-Escalation Study on the Safety of Lapatinib With Dose-Dense Paclitaxel in Patients With Platinum-Resistant Ovarian Cancer

KY

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Lapatinib	GW2016, GSK572016, lapatinib ditosylate, Tykerb	EGFR and HER2 kinase inhibitor	Approved in Other Cancers
Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Microtubule stabilizer/mitotic inhibitor	Approved in Ovarian Cancer

I

Small cell of hypercalcemic type (SCCOHT), clear cell, or endometrioid ovarian cancer with SMARCA4 or ARID1A mutations

Pilot Feasibility and Efficacy Trial of a Novel Reversible LSD1 Inhibitor SP-2577 (Seclidemstat) Plus Pembrolizumab in Select SWI/SNF-mutant Gynecologic Cancers

AZ

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Pembrolizumab	Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers
Seclidemstat	LSD1 inhibitor SP-2577, SP-2577	LSD1 inhibitor	Clinical Trials

I

Recurrent high grade serous ovarian cancer

A Phase 1 Dose-Escalation Trial of Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer

MI

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Belinostat	PXD101	HDAC inhibitor	Approved in Other Cancers
Talazoparib	MDV3800, BMN-673, Talazoparib Tosylate, Talzenna	PARP inhibitor	Approved in Other Cancers

I

Recurrent ovarian cancer (inc expansion)

Phase I, Two-Part, Multi-Center, First-in-Human Study of DS-6000a in Subjects With Advanced Renal Cell Carcinoma and Ovarian Tumors

OK, PA, TN

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
DS-6000a		ADC: anti-CDH6 + topoisomerase I inhibitor (Dxd)	Clinical Trials

I

Recurrent ovarian cancer (inc expansion)

Ph 1/1B Evaluation of the Safety, Pharmacokinetics and Efficacy of GRN-300, a Salt-inducible Kinase Inhibitor, Alone and in Combination With Paclitaxel, in Recurrent Ovarian, Primary Peritoneal, and Fallopian Tube Cancers.

TX

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
GRN-300		SIK2/3 inhibitor	Clinical Trials
Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Microtubule stabilizer/mitotic inhibitor	Approved in Ovarian Cancer

I

Advanced solid tumors (inc ovarian expansion)

A Phase 1, Open-Label, Dose Escalation Study of TH1902 in Patients With Advanced Solid Tumors and Expansion in Patients With Triple Negative Breast Cancer (TNBC), Gynecological Cancer, Colorectal Cancer, and Pancreatic Cancer

Contact research study staff

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
TH1902		ADC: anti-SORT1 + microtubule stabilizer/mitotic inhibitor (docetaxel)	Clinical Trials

I

Advanced solid tumors including those with BRCA1/2 mutations (in expansion)

Phase 1 Trial of ABT-888 and SCH727965 in Patients With Advanced Solid Tumors

MA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Dinaciclib	CDK inhibitor SCH 727965, SCH 727965	CDK1, 2, 5, 9 inhibitor	Clinical Trials
Veliparib	ABT-888	PARP inhibitor	Clinical Trials

I

Advanced ovarian cancer at first recurrence

A Phase 1 Open-label Study of the Selective Inhibitor of Nuclear Export, Selinexor (KPT-330) in Combination With Paclitaxel and Carboplatin in Patients With Advanced Ovarian or Endometrial Cancers

NJ, NY

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Carboplatin	Paraplatin, Novoplatinum	DNA damaging agent	Approved in Ovarian Cancer
Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Microtubule stabilizer/mitotic inhibitor	Approved in Ovarian Cancer
Selinexor	selective inhibitor of nuclear export KPT-330, CRM1 nuclear export inhibitor KPT-330, KPT-330, Xpovio	Selective inhibition of nuclear export (SINE)	Approved in Other Cancers

I

MUC16ecto+ recurrent high grade serous ovarian cancer (> 2 prior therapies)

A Phase I Clinical Trial of Cyclophosphamide Followed by Intravenous and Intraperitoneal Infusion of Autologous T Cells Genetically Engineered to Secrete IL-12 and to Target the MUC16ecto Antigen in Patients With Recurrent MUC16ecto+ Solid Tumors

NY

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
4H11-28z/fIL-12/EFGRt+ CAR T	4H11-28z/fIL-12/EFGRt+ genetically-modified T cells, autologous MUC16ecto-targeting EGFR-secreting T lymphocytes	Immune response against cancer expressing MUC16ecto	Clinical Trials
Cyclophosphamide	Sendoxan, Procytox, Ledoxina, Genoxal, Fosfaseron, Enduxan, Endoxana, Endoxan, Cytophosphan, Cyclostine, Cyclostin, CYCLO-cell, Cycloblastine, Cycloblastin, Cicloxal, Carloxan, Neosar, Cytoxan, Clafen, Zytoxan, Syklofosfamid, Mitoxan, Cytophosphane, Cyclophosphanum, Cyclophosphan, Cyclophosphamidum, Cyclophosphamid monohydrate, Cyclophospham, CPM, CP monohydrate, Claphene, Ciclofosfamide, Ciclofosfamida	DNA damaging agent	Approved in Ovarian Cancer
Fludarabine	Fludara Oral, 2-F-ara-AMP, Beneflur	DNA synthesis inhibitor	Approved in Other Cancers

I

Advanced solid tumors (in ovarian expansion)

Phase I Active Immunotherapy Trial With a Combination of Two Chimeric (Trastuzumab-like and Pertuzumab-like)Human Epidermal Growth Factor Receptor 2 (HER-2) B Cell Peptide Vaccine Emulsified in ISA 720 and Nor-MDP Adjuvant in Patients With Advanced Solid Tumors

OH

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
MVF-HER-2(597-626)-MVF-HER-2 (266-296) peptide vaccine	B-Vaxx	Immune response against cancer expressing HER2	Clinical Trials

I

Platinum sensitive ovarian cancer at first or second recurrence

Phase 1 Dose Escalation and Expansion Cohort of Carboplatin and Gemcitabine With or Without M6620 (VX-970) in First or Second Recurrence Platinum-Sensitive Epithelial Ovarian, Peritoneal, and Fallopian Tube Cancer

AZ, CO, FL, KY, MN, NJ, PA, VA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Berzosertib	ATR kinase inhibitor VX-970, VE-822, M6620, VX-970	ATR kinase inhibitor	Clinical Trials
Carboplatin	Paraplatin, Novoplatinum	DNA damaging agent	Approved in Ovarian Cancer
Gemcitabine	Gemzar	Ribonucleotide reductase and DNA synthesis inhibitor	Approved in Ovarian Cancer

I

Advanced solid tumors (in ovarian expansion)

Phase I Study to Evaluate the Tolerability, Efficacy, and Safety of Pazopanib in Combination With PCI-24781 in Patients With Metastatic Solid Tumors

CA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Abexinostat	HDAC inhibitor CRA-024781, PCI-24781	HDAC inhibitor
Pazopanib	Votrient	Multi-targeted RTK inhibitor

I

Advanced solid tumors (in expansion)

A Phase I Study of the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of APG-1387 as A Single Agent or in Combination With Systemic Anti-Cancer Agents in Patients With Advanced Solid Tumors or Hematologic Malignancies

MI, TX

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
APG-1387		SMAC mimetic and IAP antagonist	Clinical Trials
Carboplatin	Paraplatin, Novoplatinum	DNA damaging agent	Approved in Ovarian Cancer
Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Microtubule stabilizer/mitotic inhibitor	Approved in Ovarian Cancer
Pembrolizumab	Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers

I

Advanced solid tumors (in expansion)

A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of INCMGA00012 in Patients With Advanced Solid Tumors

AZ, MI, NJ, NC, TX, VA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Retifanlimab	INCMGA00012, anti-PD-1 monoclonal antibody MGA012, MGA012	Blocks PD-L1/2 inhibition of T cells	Clinical Trials

I

Advanced solid tumors (in expansion)

Phase Ib Study of Copanlisib in Combination With Nivolumab or With Nivolumab and Ipilmumab

MD, TX

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Copanlisib	BAY 80-6946, PI3K inhibitor BAY 80-6946	pan-PI3K inhibitor	Approved in Other Cancers
Nivolumab	BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers

I

Recurrent or refractory NY-ESO-1+ ovarian cancer

A Phase I, Open Label Study Evaluating the Safety and Efficacy of Adoptive Transfer of Autologous NY-ESO-1 CD8-TCR Engineered T Cells and NY-ESO-1 CD4-TCR Engineered Hematopoietic Stem Cells (HSC) After a Myeloablative Conditioning Regimen, With Administration of IL-2 in Patients With Recurrent or Treatment Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer

NY

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Aldesleukin	Proleukin	IL-2 receptor agonist	Approved in Other Cancers
Melphalan	Sarcolysin, Alkeran, Alkerana, Melfalan, Phenylalanine mustard	DNA damaging agent	Approved in Other Cancers
NY-ESO-1 CD4-TCR Engineered Hematopoietic Stem Cells (HSC)		Immune response against cancer expressing NY-ESO-1	Clinical Trials
NY-ESO-1 CD8-TCR Engineered T Cells		Immune response against cancer expressing NY-ESO-1	Clinical Trials

I

Recurrent or persistent mesothelin+ serous ovarian cancer

Phase I Study of Human Chimeric Antigen Receptor Modified T Cells in Patients With Mesothelin Expressing Cancers

PA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Cyclophosphamide	Sendoxan, Procytox, Ledoxina, Genoxal, Fosfaseron, Enduxan, Endoxana, Endoxan, Cytophosphan, Cyclostine, Cyclostin, CYCLO-cell, Cycloblastine, Cycloblastin, Cicloxal, Carloxan, Neosar, Cytoxan, Clafen, Zytoxan, Syklofosfamid, Mitoxan, Cytophosphane, Cyclophosphanum, Cyclophosphan, Cyclophosphamidum, Cyclophosphamid monohydrate, Cyclophospham, CPM, CP monohydrate, Claphene, Ciclofosfamide, Ciclofosfamida	DNA damaging agent	Approved in Ovarian Cancer
huCART-meso cells		Immune response against cancer expressing mesothelin	Clinical Trials

I

Recurrent or persistent FRalpha+ high grade serous ovarian cancer

Phase I Clinical Trial of Adoptive Transfer of Autologous Folate Receptor - Alpha Redirected T Cells for Recurrent High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

PA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Cyclophosphamide	Sendoxan, Procytox, Ledoxina, Genoxal, Fosfaseron, Enduxan, Endoxana, Endoxan, Cytophosphan, Cyclostine, Cyclostin, CYCLO-cell, Cycloblastine, Cycloblastin, Cicloxal, Carloxan, Neosar, Cytoxan, Clafen, Zytoxan, Syklofosfamid, Mitoxan, Cytophosphane, Cyclophosphanum, Cyclophosphan, Cyclophosphamidum, Cyclophosphamid monohydrate, Cyclophospham, CPM, CP monohydrate, Claphene, Ciclofosfamide, Ciclofosfamida	DNA damaging agent	Approved in Ovarian Cancer
Fludarabine	Fludara Oral, 2-F-ara-AMP, Beneflur	DNA synthesis inhibitor	Approved in Other Cancers
MOv19-BBz CAR T		Immune response against cancer expressing folate receptor	Clinical Trials

I

Recurrent ovarian cancer with disease in the peritoneal cavity or retroperitoneal lymph nodes (in ovarian expansion)

Phase Ib Clinical Investigation of Intraperitoneal Ipilimumab and Nivolumab in Patients With Peritoneal Carcinomatosis Due to Gynecologic Cancers

TX

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Ipilimumab	Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy	Blocks CTLA-4 inhibition of T cells	Approved in Other Cancers
Nivolumab	BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers

I

Recurrent FRalpha+ ovarian cancer, excluding platinum-sensitive at first recurrence and primary platinum refractory (in expansion)

Phase I Study of Mirvetuximab Soravtansine (IMGN853) and Rucaparib for Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer

OH

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Mirvetuximab Soravtansine	Anti-FOLR1-mab Maytansinoid Conjugate, IMGN853, M9346A-sulfo-SPDB-DM4	ADC: anti-FOLR1 + microtubule destabilizer (DM4)	Clinical Trials
Rucaparib	AG-014699, PF 01367338, CO-338, Rubraca	PARP inhibitor	Approved in Ovarian Cancer

I

Recurrent high grade serous ovarian cancer, excl. primary platinum refractory (in ovarian expansion)

A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody-Drug Conjugate (ADC), in Patients With Advanced Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) and Endometrial Cancers

CO, FL, IL, NV, NC, OH, PA, TN, WI

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
STRO-002		ADC: anti-FOLR1 + microtubule destabilizer (SC209)	Clinical Trials

I

Ovarian cancer with an indication for palliative radiation therapy

An Open Label, Phase Ia/Ib Trial of the DNA-PK Inhibitor MSC2490484A in Combination With Radiotherapy in Patients With Advanced Solid Tumors

FL, NY, PA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Cisplatin	CACP, cis-DDP, cis-platinum, CDDP, Platinol, Abiplatin, Blastolem, Briplatin, Cisplatyl, Citoplatino, Citosin, Lederplatin, Metaplatin, Neoplatin, Placis, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platiran, Platistin, Platosin	DNA damaging agent	Approved in Ovarian Cancer
Nedisertib	M3814, DNA-PK inhibitor MSC2490484A, Peposertib	DNA-PK inhibitor	Clinical Trials
Radiation Therapy	Radiotherapy, Irradiation

I

Advanced solid tumors (inc ovarian expansion)

A Phase 1 Study of TJ011133 Administered Alone or in Combination With Pembrolizumab or Rituximab in Subjects With Relapsed/Refractory Advanced Solid Tumors and Lymphoma

AL, AZ, CA, CT, FL, IN, MI, MN, NY, TN, WA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Lemzoparlimab	TJ011133, TJC4	Blocks CD47 signaling to stimulate immune response and tumor cell phagocytosis	Clinical Trials
Pembrolizumab	Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers

I

Recurrent ovarian cancer with progression on prior PARP inhibitor (inc expansion)

Trial of M4344 and Niraparib in Patients With PARP Resistant Recurrent Ovarian Cancer

AL

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
M4344	VX-803	ATR kinase inhibitor	Clinical Trials
Niraparib	MK4827, Zejula	PARP inhibitor	Approved in Ovarian Cancer

I

Recurrent ovarian cancer (inc expansion)

A Phase I/Ib Dose Escalation Study of Pegylated Liposomal Doxorubicin (PLD) With Peposertib (M3814) in Platinum - Resistant or Ineligible Ovarian and Related Cancers With Planned Expansions in High Grade Serous (HGSOC) and Low Grade Serous Ovarian Cancer (LGSOC)

MA, NJ, NY, OK, VA, WI

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Liposomal doxorubicin	Pegylated Liposomal Doxorubicin Hydrochloride, liposomal doxorubicin, LipoDox, Evacet, Dox-SL, Doxil	Topoisomerase II inhibitor	Approved in Ovarian Cancer
Nedisertib	M3814, DNA-PK inhibitor MSC2490484A, Peposertib	DNA-PK inhibitor	Clinical Trials

I

Advanced solid tumors (inc ovarian expansion)

A Phase I Dose Escalation Study of NMS-03305293 in Adult Patients With Selected Advanced/Metastatic Solid Tumors

TX

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
NMS-03305293		PARP inhibitor	Clinical Trials

I

Advanced solid tumors (in expansion)

A Phase 1/1b Multicenter Study to Evaluate the Humanized Anti-CD73 Antibody, CPI-006, as a Single Agent or in Combination With Ciforadenant, With Pembrolizumab, and With Ciforadenant Plus Pembrolizumab in Adult Subjects With Advanced Cancers

AZ, CA, CT, FL, IL, MD, MA, NV, NY, NC, OH, OK, PA, SC, TN, TX, VA, WI

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Ciforadenant	adenosine-A2A receptor antagonist CPI-444, CPI-444	Blocks adenosine A2A receptor inhibition of T cells	Clinical Trials
CPI-006	anti-CD73 monoclonal antibody CPI-006, CPX-006	Blocks Ecto-5-nucleotidase (CD73) inhibition of T cells	Clinical Trials
Pembrolizumab	Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers

I

Recurrent ovarian cancer (amenable to radiation therapy) - without ascites

Phase I Study of Talazoparib in Combination With Radiation Therapy for Locally Recurrent Gynecologic Cancers

TX

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Radiation Therapy	Radiotherapy, Irradiation
Talazoparib	MDV3800, BMN-673, Talazoparib Tosylate, Talzenna	PARP inhibitor	Approved in Other Cancers

I

Advanced solid tumors, including HER2+ cohort (in ovarian expansion)

A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of MGD013, A Bispecific DART® Protein Binding PD-1 and LAG-3 in Patients With Unresectable or Metastatic Neoplasms

AZ, CA, FL, IL, MD, MA, NC, OH, OK, PA, TN, TX

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Margetuximab-cmkb	anti-HER2 monoclonal antibody MGAH22 margetuximab, anti-HER2 mAb MGAH22, anti-HER2/c-erbB2 monoclonal antibody	HER2 antagonist	Approved in Other Cancers
Tebotelimab	MGD013, dual-affinity retargeting protein MGD013, anti-PD-1/anti-LAG-3 DART protein MGD013	Blocks LAG-3 and PD-1 inhibition of T cells	Clinical Trials

If you have any questions or would like help with your search, please call us at: 858-264-5124 or email us at patientsupport@clearityfoundation.org.